title: Bilateral subthalamotomy in Parkinson's disease: initial and long-term response.
abstract: We conducted an open label pilot study of the effect of bilateral subthalamotomy in 18 patients with advanced Parkinson's disease. In seven patients, the first subthalamotomy pre-dated the second by 12-24 months ('staged surgery'). Subsequently, a second group of 11 patients received bilateral subthalamotomy on the same day ('simultaneous surgery'). Patients were assessed according to the CAPIT (Core Assessment Program for Intracerebral Transplantation) protocol, a battery of timed motor tests and neuropsychological tests. Evaluations were performed in the 'off' and 'on' drug states before surgery and at 1 and 6 months and every year thereafter for a minimum of 3 years after bilateral subthalamotomy. Compared with baseline, bilateral subthalamotomy induced a significant (P < 0.001) reduction in the 'off' (49.5%) and 'on' (35.5%) Unified Parkinson's Disease Rating Scale (UPDRS) motor scores at the last assessment. A blind rating of videotape motor exams in the 'off' and 'on' medication states preoperatively and at 2 years postoperatively also revealed a significant improvement. All of the cardinal features of Parkinson's disease as well as activities of daily living (ADL) scores significantly improved (P < 0.01). Levodopa-induced dyskinesias were reduced by 50% (P < 0.01), and the mean daily levodopa dose was reduced by 47% at the time of the last evaluation compared with baseline (P < 0.0001). Dyskinesias occurred intraoperatively or in the immediate postoperative hours in 13 patients, but were generally mild and short lasting. Three patients developed severe generalized chorea that gradually resolved within the next 3-6 months. Three patients experienced severe and persistent postoperative dysarthria. In two, this coincided with the patients exhibiting large bilateral lesions also suffering from severe dyskinesias. No patient exhibited permanent cognitive impairment. The motor benefit has persisted for a follow-up of 3-6 years. This study indicates that bilateral subthalamotomy may induce a significant and long-lasting improvement of advanced Parkinson's disease, but the clinical outcome was variable. This variability may depend in large part on the precise location and volume of the lesions. Further refinement of the surgical procedure is mandatory.
authors.affiliation: Movement Disorders and Neurophysiology Units, Centro Internacional de Restauracion Neurologica (CIREN), La Habana, Cuba.
authors.forename: L
authors.initials: L
authors.lastname: Alvarez
authors.forename: R
authors.initials: R
authors.lastname: Macias
authors.forename: G
authors.initials: G
authors.lastname: Lopez
authors.forename: E
authors.initials: E
authors.lastname: Alvarez
authors.forename: N
authors.initials: N
authors.lastname: Pavon
authors.forename: M C
authors.initials: MC
authors.lastname: Rodriguez-Oroz
authors.forename: J L
authors.initials: JL
authors.lastname: Juncos
authors.forename: C
authors.initials: C
authors.lastname: Maragoto
authors.forename: J
authors.initials: J
authors.lastname: Guridi
authors.forename: I
authors.initials: I
authors.lastname: Litvan
authors.forename: E S
authors.initials: ES
authors.lastname: Tolosa
authors.forename: W
authors.initials: W
authors.lastname: Koller
authors.forename: J
authors.initials: J
authors.lastname: Vitek
authors.forename: M R
authors.initials: MR
authors.lastname: DeLong
authors.forename: J A
authors.initials: JA
authors.lastname: Obeso
mesh_terms: D000203:Activities of Daily Living; D000328:Adult; D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects; D003071:Cognition; D003131:Combined Modality Therapy; D004334:Drug Administration Schedule; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D009048:Motor Skills; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000473:pathology / Q000503:physiopathology / Q000601:surgery*; D010865:Pilot Projects; D011183:Postoperative Complications; D016634:Radiosurgery / Q000379:methods*; D020531:Subthalamic Nucleus / Q000601:surgery*; D016896:Treatment Outcome
chemical_list: D000978:Antiparkinson Agents; D007980:Levodopa